Among patients at a high risk of bleeding undergoing PCI with the XIENCE stent, a short dual antiplatelet therapy (DAPT) regimen of one or three months was noninferior to standard DAPT up to 12 months in terms of ischemic outcomes, according to findings from the XIENCE Short DAPT Program presented Oct. 15 during TCT 2020.

Presenting investigators Roxana Mehran, MD, FACC, and Marco Valgimigli, MD, PhD, also noted similar rates of clinically relevant (BARC 2-5) bleeding, with a significant reduction in major bleeding (BARC 3-5), and very low incidence of stent thrombosis.

Overall, the study aimed to evaluate the safety (all death or myocardial infarction) of a short DAPT regimen compared with a longer one, as well as determine the impact of short DAPT on clinically relevant bleeding and evaluate stent thrombosis. It was not a randomized trial. Key inclusion criteria included: history of stroke, chronic kidney disease, anemia, major bleeding in the last 12 months, and over the age of 75.

Mehran and Valgimigli noted several limitations to the study, including that the findings may not be generalizable to patients who do not meet the study’s inclusion/exclusions criteria. Additionally, “the observed treatment effect only applies to patients ‘free’ from adverse events and adherent to the DAPT treatment regimen for the first one to three months,” they added.

Clinical Topics: Invasive Cardiovascular Angiography and Intervention

Keywords: TCT20, Transcatheter Cardiovascular Therapeutics, Percutaneous Coronary Intervention, Drug-Eluting Stents

< Back to Listings